LEXICON PHARMACEUTICALS, INC. 8-K

What Happened

• Lexicon Pharmaceuticals, Inc. announced a public offering and related private placements. On January 29, 2026 the company signed an Underwriting Agreement with Jefferies LLC and Piper Sandler & Co.; the public offering priced at $1.30 per share. The public offering closed concurrently with private placements on February 2, 2026. A press release announcing the pricing was issued January 30, 2026.
• The offering package includes a 32,000,000-share sale of common stock at $1.30 per share (gross proceeds ≈ $41.6M) with a 30‑day underwriter option to purchase up to 4,800,000 additional shares (increasing public gross proceeds to ≈ $47.84M if exercised). Affiliates of Invus purchased 22,400,000 common shares concurrently (Private Placement) for $29.12M. Separately, an Invus affiliate bought Series B Convertible Preferred Stock in a private placement (initial sale proceeds ≈ $23.86M; option could increase to $30.03M). Each preferred share converts into 50 shares of common stock (subject to the Certificate of Designations).

Key Details

• Public offering: 32,000,000 common shares at $1.30/share; gross proceeds ≈ $41.6M (≈ $47.84M if underwriters fully exercise option).
• Concurrent private placement: 22,400,000 common shares purchased by Invus affiliates at $1.30/share for $29.12M.
• Preferred private placement: initial sale ≈ $23.86M of Series B convertible preferred at $65/share (option could raise to ≈ $30.03M); conversion ratio = 1 preferred → 50 common (subject to conditions).
• Ownership impact: after the offerings and conversion of the preferred, Invus Entities are expected to hold approximately 51% of outstanding common stock. Company agreed to a 60‑day lock‑up on most stock issuances; private placements rely on Section 4(a)(2) exemptions.

Why It Matters

• Capital and control: The transactions raise a substantial amount of cash (combined gross proceeds roughly $94.6M under base scenarios; up to ≈ $107.0M if all options are exercised), which can support operations or development programs. At the same time, Invus’s holdings rising to ~51% creates a majority holder, which can materially affect corporate control and governance.
• Dilution and conversion risk: Existing common shareholders will face dilution from the new common shares and potential conversion of preferred shares (convertible at 50:1). Investors should note the lock-up and that private placements were unregistered and sold under exemptions.
• Next steps for investors: Review company disclosures (shelf registration and Certificate of Designations) for conversion mechanics and any governance changes; monitor any SEC filings and company updates about use of proceeds and board/leadership actions following Invus’s increased stake.